Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ATOS
Stock Latest News
The Fly
Atossa Therapeutics management to meet virtually with Craig-Hallum
2d ago
ATOS
Premium
Ratings
Strategic Adjustments and Promising Data Bolster Atossa Therapeutics’ Buy Rating
3d ago
ATOS
Premium
Ratings
Promising Potential of Atossa Therapeutics’ Endoxifen in Metastatic Breast Cancer Treatment
6d ago
ATOS
Premium
Company Announcements
Atossa Therapeutics Releases Updated Corporate Presentation
13d ago
8K
ATOS
Premium
Ratings
Atossa Therapeutics: Strategic Advancements and Strong Financial Position Signal Promising Future
22d ago
ATOS
Premium
The Fly
Atossa Therapeutics appoints CORE IR for investor relations
23d ago
ATOS
Premium
Ratings
Buy Rating Supported by Atossa Therapeutics’ Strategic Advancements in Z-endoxifen Development for Breast Cancer Treatment
1M ago
ATOS
Premium
Company Announcements
Atossa Therapeutics Announces New Regulatory Strategy
1M ago
8K
ATOS
Premium
The Fly
Atossa Therapeutics has requested Type C meeting with U.S. FDA
1M ago
ATOS
Premium
Company Announcements
Atossa Therapeutics Receives Nasdaq Non-Compliance Notice
2M ago
8K
ATOS
Premium
The Fly
Atossa selects PSI for Z-endoxifen monotherapy study
2M ago
ATOS
Premium
Ratings
Buy Rating for Atossa Therapeutics: Strong Financials and Promising Endoxifen Developments
2M ago
ATOS
Premium
Company Announcements
Atossa Therapeutics Advances Breast Cancer Treatments
2M ago
ATOS
Premium
Ratings
Positive FDA Feedback and Promising Phase 2 Results Justify Buy Rating for Atossa Therapeutics
2M ago
ATOS
Premium
The Fly
Atossa Therapeutics reports Q2 EPS (7c), consensus (6c)
2M ago
ATOS
Premium
Ratings
Optimistic Buy Rating for Atossa Therapeutics Driven by Promising Developments and Strong Financial Health
2M ago
ATOS
Premium
Ratings
Positive FDA Feedback and Strategic Advancements Boost Atossa Therapeutics’ Clinical Outlook
2M ago
ATOS
Premium
The Fly
Atossa Therapeutics reports ‘positive’ FDA feedback regarding (Z)-endoxifen
2M ago
ATOS
Premium
The Fly
Craig-Hallum bullish on Atossa Therapeutics, initiates with a Buy
4M ago
ATOS
Premium
The Fly
Atossa Therapeutics initiated with a Buy at Craig-Hallum
4M ago
ATOS
Premium
Company Announcements
Atossa Therapeutics Reports Q1 2025 Financial Results
4M ago
ATOS
Premium
Ratings
Atossa Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
5M ago
ATOS
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
